Short Interest in Aclarion, Inc. (NASDAQ:ACON) Drops By 11.2%

Aclarion, Inc. (NASDAQ:ACON) was the target of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 380,900 shares, a drop of 11.2% from the October 31st total of 428,800 shares. Currently, 3.8% of the shares of the company are sold short. Based on an average daily trading volume, of 480,800 shares, the short-interest ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets lowered their target price on Aclarion from $1.50 to $1.30 and set a “buy” rating on the stock in a research note on Wednesday, November 27th.

Aclarion Price Performance

Shares of NASDAQ ACON opened at $0.18 on Tuesday. The firm’s 50 day simple moving average is $0.18 and its 200-day simple moving average is $0.24. Aclarion has a 12 month low of $0.16 and a 12 month high of $7.40.

Institutional Trading of Aclarion

A hedge fund recently bought a new stake in Aclarion stock. Virtu Financial LLC bought a new position in shares of Aclarion, Inc. (NASDAQ:ACON) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 1.40% of Aclarion as of its most recent SEC filing. Hedge funds and other institutional investors own 7.52% of the company’s stock.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.